Home » Stocks » ACER

Acer Therapeutics Inc. (ACER)

Stock Price: $2.87 USD 0.02 (0.70%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 41.07M
Revenue (ttm) n/a
Net Income (ttm) -22.89M
Shares Out 11.12M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.87
Previous Close $2.85
Change ($) 0.02
Change (%) 0.70%
Day's Open 2.81
Day's Range 2.50 - 2.90
Day's Volume 211,171
52-Week Range 1.08 - 5.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...

GlobeNewsWire - 3 weeks ago

Targeting a pre-NDA meeting with FDA in Q2 2021 Targeting a pre-NDA meeting with FDA in Q2 2021

GlobeNewsWire - 1 month ago

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

GlobeNewsWire - 2 months ago

Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

GlobeNewsWire - 3 months ago

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $ACER #ACER--ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.

GlobeNewsWire - 5 months ago

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...

GlobeNewsWire - 6 months ago

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies fo...

GlobeNewsWire - 6 months ago

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders

Business Wire - 7 months ago

SAN DIEGO & NEWTON, Mass.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc.

Business Wire - 7 months ago

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutic...

GlobeNewsWire - 7 months ago

Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to cu...

Business Wire - 8 months ago

LOS ANGELES--(BUSINESS WIRE)---- $ACER #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the ...

GlobeNewsWire - 9 months ago

Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital Expanded pipel...

GlobeNewsWire - 10 months ago

NEWTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies f...

Zacks Investment Research - 10 months ago

Per IDC, PC shipments decline 9.8% in Q1 despite strong demand, as the global lockdown hurt supply chains and productions all over.

Other stocks mentioned: HPQ, LNVGY, AAPL, DELL
Seeking Alpha - 11 months ago

Acer Therapeutics: EDSIVO Appeal Denied But FDA Door Remains Open

GlobeNewsWire - 11 months ago

Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™ Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™

GlobeNewsWire - 1 year ago

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data Anticipate submitting New Drug App...

Seeking Alpha - 1 year ago

Acer Therapeutics: Upcoming Catalysts

GlobeNewsWire - 1 year ago

Part A Successfully Completed and Optimal Formulation of ACER-001 Identified

GlobeNewsWire - 1 year ago

Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

The Motley Fool - 1 year ago

There are several good reasons that two consecutive quarters of improved personal computer purchases could become three, and then four, or more.

Other stocks mentioned: DELL, AAPL, HPQ, LNVGY
Seeking Alpha - 1 year ago

Acer's share price plummeted following a CRL issued by the FDA in late June for Acer's lead drug candidate EDSIVO for the treatment of vEDS patients with COL3A1 + mutation.

GlobeNewsWire - 1 year ago

NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies fo...

Benzinga - 1 year ago

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Other stocks mentioned: BHVN, CELG, ITCI, KPTI, MRK
Zacks Investment Research - 1 year ago

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

InvestorPlace - 1 year ago

Acer Therapeutics news for Tuesday concerning a rejection letter from the U.S. Food and Drug Administration is pummeling ACER stock.

Benzinga - 1 year ago

Acer Therapeutics Inc (NASDAQ: ACER) shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo i...

Market Watch - 1 year ago

Acer Therapeutics Inc. said Tuesday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its new drug application (NDA) for Edsivo, a treatment of ...

Seeking Alpha - 1 year ago

Acer Therapeutics has 3 clinical stage drug candidates targeting serious orphan and ultra-orphan diseases with significant unmet medical needs.

Benzinga - 1 year ago

Laura Chico maintained an Outperform rating on Acer Therapeutics with an unchanged $48 price target.

Seeking Alpha - 1 year ago

Acer's share price has recently dropped significantly along with other biotech companies.

About ACER

Acer Therapeutics, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of indu... [Read more...]

Industry
Biotechnology
Founded
2013
CEO
Christopher Schelling
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
ACER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACER stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 248.43% from the latest price.

Price Target
$10.00
(248.43% upside)
Analyst Consensus: Buy